Clinical trials: Pre-Menopause
Endometriosis
A Study to Investigate Efficacy and Safety of OG-6219 BID in 3 Dose Levels Compared With Placebo in Participants Aged 18 to 49 With Moderate to Severe Endometriosis-related Pain
The purpose of this global Phase 2 study is to determine the efficacy, safety, and tolerability of 3 dose levels of OG-6219 in pre-menopausal women between 18 and 49 years of age (inclusive), who have moderate to severe…
- Trial name
- ELENA (NCT05560646)
- Testing
- OG-6219
- Where
- 86 sites in United States, Belgium and 9 more
- Volunteers
- 354 people
- Sponsor
- Organon and Co
Depression, Healthy
Bone Loss in Premenopausal Women With Depression
The purpose of this study is to determine whether women with major depression lose bone mass at a faster rate than women without depression.
- Conditions
- Depression, Healthy, Osteopenia, Osteoporosis
- Trial name
- NCT00006180
- Testing
- Alendronate
- Where
- United States
- Volunteers
- 220 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Pre-Menopause, Irregular Menstruation
Online Cognitive Awareness-Based Nursing Support for Premenopausal
This randomized controlled study was conducted at Istanbul University-Cerrahpaşa Cerrahpaşa Medical Faculty Hospital between 16.05.2022-30.06.2023. Research data were collected at the gynecology outpatient clinic.
- Trial name
- (MenoMind) (NCT06196372)
- Testing
- MenoMind intervention group
- Where
- Turkey (Türkiye)
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Bandırma Onyedi Eylül University
Estrogen Receptor-positive Breast Cancer, Progesterone Receptor Positive Tumor
Pilot Study Estradiol Followed by Exemestane Hormone Receptor + Metastatic Breast Cancer
RATIONALE: Estrogen can cause the growth of tumor cells. Hormone therapy using therapeutic estradiol may fight breast cancer by lowering the amount of estrogen the body makes.
- Conditions
- Estrogen Receptor-positive Breast Cancer, Progesterone Receptor Positive Tumor, Recurrent Breast Cancer, Stage IIIC Breast Cancer
- Trial name
- NCT01385280
- Testing
- therapeutic estradiol, exemestane, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Arizona
Invasive Breast Cancer
AKT Inhibitor in Oestrogen Positive Breast Cancer
To compare the effect of four and a half days treatment of a range of doses of AZD5363 on selected markers of the AKT pathway and anti-proliferation compared with placebo in oestrogen receptor positive breast cancers.
- Trial name
- STAKT (NCT02077569)
- Testing
- AZD5363
- Where
- 11 sites in United Kingdom
- Volunteers
- 48 people
- Sponsor
- University of Nottingham
Breast Cancer, Insulin Resistance
Insulin Resistance and Breast Cancer
This study will characterize risk factors associated with breast cancer development in some patients. In particular, it will examine the role of insulin in breast cancer in patients with and without a family history of the…
- Trial name
- NCT00304941
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Estrogen Deficiency, Cardiovascular Disease (CVD)
Atherosclerosis, Immune Mediated Inflammation and Hypoestrogenemia in Young Women
The purpose of this study is to determine whether young women with functional hypothalamic amenorrhea (premenopausal HypoE) is associated with risk factors for pre-clinical cardiovascular disease (CVD).
- Conditions
- Estrogen Deficiency, Cardiovascular Disease (CVD), Functional Hypothalamic Amenorrhea, Endothelial Dysfunction
- Trial name
- NCT03018366
- Testing
- 17beta Estradiol, Progesterone
- Where
- United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Cedars-Sinai Medical Center
Breast Cancer
Effect of a Natural Health Product on Urinary Estrogen Metabolites
The purpose of this study is to determine if a supplemental formula can beneficially alter the ratio of urinary estrogen metabolites.
- Trial name
- NCT01089049
- Testing
- FemMED Breast Health Formula
- Where
- Canada
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- Nutrasource Pharmaceutical and Nutraceutical Services, Inc.
Breast Cancer
PROACT - Pre-Operative Arimidex Compared To Tamoxifen
The purpose of this study is to compare tamoxifen, versus a newer treatment, ARIMIDEX, which we already know to be well tolerated.
- Trial name
- NCT00232661
- Testing
- ARIMIDEX (anastrazole), NOLVADEX (tamoxifen)
- Where
- 79 sites in United States, Belgium and 8 more
- Volunteers
- 452 people
- Sponsor
- AstraZeneca
Iron Deficiency Anaemia Due to Dietary Causes
Measuring Iron Bioavailability From Oral Iron Supplements in Healthy Pre-menopausal Women Using Stable Isotopes
In this study the investigators will compare iron absorption from 3 doses of iron (5, 10, 15 mg, given as either Spatone™ or ferrous sulphate).
- Trial name
- BOIs (NCT07563686)
- Testing
- 5mg Spatone, 10mg Spatone, 15mg Spatone
- Where
- United Kingdom
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- King's College London
Overweight and Obesity
Betaine Supplementation and Lipid Metabolism in Overweight and Obese Pre-menopausal Women
Obesity represents a serious global health issue with significant consequences, including an increased risk of chronic diseases.
- Trial name
- NCT06344377
- Testing
- Betaine
- Where
- Poland
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Poznan University of Life Sciences
Overactive Bladder (OAB), Menopause
Effect of Vaginal Estrogen on Alterations in the Urine Microbiome of Menopausal Women With Overactive Bladder
The goal of this Pre-Post Quasi-experimental study is to investigates the effect of vaginal estrogen therapy on changes in the urinary microbiome and its association with improvement in overactive bladder (OAB) symptoms in…
- Conditions
- Overactive Bladder (OAB), Menopause, Microbiome
- Trial name
- NCT06780163
- Testing
- 17β-estradiol 10 mcg
- Where
- Thailand
- Volunteers
- 30 people
- Sponsor
- Mahidol University
Uterine Fibroids
Extension Study of Proellex in Women Who Have Previously Completed Study ZPU 003
ZPU-003 EXT is a 2-year extension study of ZPU-003 (NCT00882258) to determine the continued safety and efficacy of Proellex in women who have previously completed the double-blind portion of the study.
- Trial name
- NCT00958334
- Testing
- Proellex®
- Where
- 11 sites in United States
- Volunteers
- 65 people
- Sponsor
- Repros Therapeutics Inc.
Breast Cancer
A Study of LY3484356 in Women With Breast Cancer Before Having Surgery
The purpose for this study is to see if the study drug, LY3484356, is safe and to determine what effects it has on breast cancer in participants with Estrogen Receptor Positive (ER+), HER2 Negative (HER2-) early stage (stage…
- Trial name
- EMBER-2 (NCT04647487)
- Testing
- LY3484356
- Where
- 19 sites in United States, Belgium and 4 more
- Volunteers
- 87 people
- Sponsor
- Eli Lilly and Company
Sexual Dysfunction, Physiological
Vaginal Heat Wash-out (HWO) in 4 Groups of Women (Pre- and Postmenopausal With and Without Female Sexual Arousal Disorder (FSAD)).
The Pfizer developed Heat Wash-Out (HWO) system is a software controlled electromechanical system designed to measure vaginal wall blood flow. A small vaginal probe is attached to a control unit.
- Trial name
- FSAD HWO VBF (NCT00443248)
- Testing
- Vaginal Heat Wash-Out Device
- Where
- 2 sites in Australia
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Pfizer
Breast Cancer
Letrozole in Treating Postmenopausal Women With Stage I, II or III Breast Cancer That Can Be Removed by Surgery
RATIONALE: Hormone therapy using letrozole may fight breast cancer by lowering the amount of estrogen the body makes. Giving letrozole before surgery allows us to monitor the effects of letrozole on the tumor on a molecular level…
- Trial name
- NCT00651976
- Testing
- letrozole, Blood Collection, biopsy/lumpectomy/mastectomy
- Where
- 5 sites in United States
- Volunteers
- 213 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Early-stage Breast Cancer, Hormone Receptor Positive Tumor
A Window of Opportunity Study of Pre-operative Endocrine Therapy With and Without Prometrium in Postmenopausal Women With Early Stage Breast Hormone Receptor Positive (HR+) Human Epidermal Receptor 2 Negative (HER2-) Breast Cancer.
A phase II randomised, open label study of pre-operative endocrine therapy with \& without prometrium in postmenopausal women with early stage breast hormone receptor positive (HR+) human epidermal receptor 2 negative (HER2-)…
- Trial name
- WinPro (NCT03906669)
- Testing
- Letrozole, Letrozole and Prometrium, Tamoxifen and Prometrium
- Where
- Australia
- Volunteers
- 200 people
- Sponsor
- St Vincent's Hospital
Breast Cancer
Neoadjuvant Lenvatinib Combined With Letrozole in Hormone Receptor Positive Breast Cancer
This is a single-centre study comprising two phases: a lead-in phase Ib and a phase II randomized portion. Lead-in Phase Ib study A lead-in phase I study will be built into this protocol to confirm the dose of lenvatinib that can…
- Trial name
- NCT02562118
- Testing
- Lenvatinib + Letrozole
- Where
- Singapore
- Volunteers
- 40 people
- Sponsor
- National University Hospital, Singapore
Cystic Fibrosis, Hypoestrogenism
Estrogen Supplementation and Bone Health in Women With CF
The goal of this study is to learn about the role of estrogen and other hormones in bone development in adolescent and young adult women with cystic fibrosis (CF).
- Trial name
- STURDY (NCT05704036)
- Testing
- Transdermal estrogen, Progesterone
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Johns Hopkins University
Healthy, Premenopausal Period
Effects of Omega-3 Fatty Acids on Risk Factors for Breast Cancer in Pre-menopausal Women
Healthy premenopausal women were enrolled in a diet intervention study that examined the effect of a combination EPA/DHA supplement on risk factors associated with breast cancer.
- Trial name
- NCT02816125
- Testing
- omega-3 fatty acid
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- University of Guelph